Journal article · 2009
Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP–ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells
Bioorganic & Medicinal Chemistry Letters, 20(3), 1100–1105 · Published 24 November 2009 · DOI 10.1016/j.bmcl.2009.11.087
In brief
“Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP–ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells” is a 2009 journal article by Federica Ferrigno and 11 co-authors, published in Bioorganic & Medicinal Chemistry Letters. OpenAlex counts 19 citations as of 19 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 19
- Most cited in
- 2024 (4)
- Field-weighted impact
- 0.35
- References
- 13
- Authors
- 12
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Ferrigno, F., Branca, D., Kinzel, O. D., Lillini, S., Bufi, L. L., Monteagudo, E. S., Muraglia, E., Rowley, M., Schultz‐Fademrecht, C., Toniatti, C., Torrisi, C., & JONES, P. G. (2009). Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP–ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells. Bioorganic & Medicinal Chemistry Letters, 20(3), 1100–1105. https://doi.org/10.1016/j.bmcl.2009.11.087
MLA 9
Ferrigno, Federica, et al. “Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP–ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells.” Bioorganic & Medicinal Chemistry Letters, vol. 20, no. 3, 2009, pp. 1100–1105. https://doi.org/10.1016/j.bmcl.2009.11.087.
Chicago
Ferrigno, Federica, Danila Branca, Olaf D. Kinzel, Samuele Lillini, Laura Llauger Bufi, Edith S. Monteagudo, Ester Muraglia, et al. 2009. “Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP–ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells.” Bioorganic & Medicinal Chemistry Letters 20 (3): 1100–1105. https://doi.org/10.1016/j.bmcl.2009.11.087.
Harvard
Ferrigno, F. et al. (2009) ‘Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP–ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells’, Bioorganic & Medicinal Chemistry Letters, 20(3), pp. 1100–1105. doi:10.1016/j.bmcl.2009.11.087.
IEEE
F. Ferrigno et al., “Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP–ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells,” Bioorganic & Medicinal Chemistry Letters, vol. 20, no. 3, pp. 1100–1105, 2009, doi: 10.1016/j.bmcl.2009.11.087.
BibTeX
@article{ferrigno2009development,
title = {{Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP–ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells}},
author = {Ferrigno, Federica and Branca, Danila and Kinzel, Olaf D. and Lillini, Samuele and Bufi, Laura Llauger and Monteagudo, Edith S. and Muraglia, Ester and Rowley, Michael and Schultz‐Fademrecht, Carsten and Toniatti, Carlo and Torrisi, Caterina and JONES, PHILIP G.},
journal = {Bioorganic \& Medicinal Chemistry Letters},
year = {2009},
volume = {20},
number = {3},
pages = {1100--1105},
doi = {10.1016/j.bmcl.2009.11.087},
url = {https://doi.org/10.1016/j.bmcl.2009.11.087}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2012 | 1 | |
| 2013 | 2 | |
| 2014 | 3 | |
| 2015 | 1 | |
| 2016 | 2 | |
| 2020 | 1 | |
| 2022 | 1 | |
| 2023 | 2 | |
| 2024 | 4 | |
| 2025 | 1 |
Its field-weighted citation impact is 0.35: it has been cited 0.35 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- PARP-1 inhibitors
- pyridazinone derivatives
- structure-activity relationship
- anticancer agents
- hERG selectivity
- cytochrome P450 inhibition
- drug metabolism
- pharmacokinetics
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Ferrigno, F., Branca, D., Kinzel, O. D., Lillini, S., Bufi, L. L., Monteagudo, E. S., Muraglia, E., Rowley, M., Schultz‐Fademrecht, C., Toniatti, C., Torrisi, C., & JONES, P. G. (2009). Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP–ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells. Bioorganic & Medicinal Chemistry Letters, 20(3), 1100–1105. https://doi.org/10.1016/j.bmcl.2009.11.087
How many times has this paper been cited?
19 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Federica Ferrigno, Danila Branca, Olaf D. Kinzel, Samuele Lillini, Laura Llauger Bufi, Edith S. Monteagudo, Ester Muraglia, Michael Rowley, Carsten Schultz‐Fademrecht, Carlo Toniatti, Caterina Torrisi, PHILIP G. JONES.
What is the DOI of this paper?
10.1016/j.bmcl.2009.11.087, permanently at https://doi.org/10.1016/j.bmcl.2009.11.087. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.